Disc Medicine Inc
IRON60.790USD
-1.840-2.94%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
2.11BMarket Cap
LossP/E TTM
More Details of Disc Medicine Inc Company
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Company Info
Ticker SymbolIRON
Company nameDisc Medicine Inc
IPO dateAug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
Number of employees84
Security typeOrdinary Share
Fiscal year-endAug 12
Address321 Arsenal Street, Suite 101
CityWATERTOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02472
Phone16176749274
Websitehttps://www.discmedicine.com/
Ticker SymbolIRON
IPO dateAug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 3
Updated: Wed, Sep 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
Other
65.03%
Shareholders
Shareholders
Proportion
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
Other
65.03%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.71%
Investment Advisor/Hedge Fund
18.24%
Hedge Fund
17.94%
Venture Capital
12.84%
Corporation
10.24%
Private Equity
9.90%
Research Firm
1.45%
Sovereign Wealth Fund
0.83%
Individual Investor
0.47%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
2023Q2
190
22.86M
100.53%
+3.93M
2023Q1
169
18.38M
96.84%
-1.35M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Access Industries, Inc.
3.56M
10.27%
--
--
Feb 27, 2025
Fidelity Management & Research Company LLC
3.05M
8.81%
+1.32M
+76.31%
Mar 31, 2025
Atlas Venture
2.38M
6.88%
-125.00K
-4.98%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.75M
5.06%
+219.74K
+14.35%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.75M
5.07%
--
--
Mar 31, 2025
RA Capital Management, LP
1.58M
4.55%
+1.58M
--
Mar 31, 2025
Janus Henderson Investors
1.42M
4.11%
+205.44K
+16.87%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.34M
3.87%
-36.42K
-2.65%
Mar 31, 2025
Wellington Management Company, LLP
2.34M
6.77%
+948.09K
+67.94%
Mar 31, 2025
OrbiMed Advisors, LLC
1.42M
4.09%
-370.55K
-20.75%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
Proshares Ultra Russell 2000
0.06%
Global X Russell 2000 ETF
0.06%
ProShares UltraPro Russell2000
0.06%
First Trust US Equity Opportunities ETF
0.06%
iShares Morningstar Small-Cap Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
Fidelity MSCI Health Care Index ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.09%
Proshares Ultra Russell 2000
Proportion0.06%
Global X Russell 2000 ETF
Proportion0.06%
ProShares UltraPro Russell2000
Proportion0.06%
First Trust US Equity Opportunities ETF
Proportion0.06%
iShares Morningstar Small-Cap Value ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.02%
Fidelity MSCI Health Care Index ETF
Proportion0.02%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Date
Type
Ratio
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
